Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Rapid Initiation of ART

In this on-demand recording of a live webinar, expert faculty review key considerations for rapid initiation of ART. Topics include current recommendations and a discussion of the data to support ART options for rapid initiation.
Jason Halperin, MD, MPH
Jürgen K. Rockstroh, MD
Released: September 29, 2021

In this episode from the series “Key Decisions in HIV Care,” Jason Halperin, MD, MPH, and Jürgen K. Rockstroh, MD, discuss important considerations in the rapid initiation of ART, including guideline recommendations and data supporting recommended ART regimen options for rapid initiation and emerging data for the 2-drug regimen dolutegravir/lamivudine for rapid start from the STAT study. Following their dialogue, the faculty field questions from healthcare professionals.

Information on this Educational Activity

Faculty

Jason Halperin, MD, MPH

Assistant Professor of Medicine
Department of Infectious Diseases
Tulane University
Infectious Disease Physician
CrescentCare
New Orleans, Louisiana

Jason Halperin, MD, MPH, has no relevant conflict of interest to report.
Jürgen K. Rockstroh, MD

Professor of Medicine
University Hospital Bonn
Department of Medicine I
Bonn, Germany

Jürgen K. Rockstroh, MD, has disclosed that he has received consulting fees from Abivax, Galapagos, Gilead Sciences, Merck, and ViiV and fees for non-CME/CE services from Gilead Sciences, Janssen, Merck, Theratechnologies, and ViiV.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Expert HIV faculty analyze new data from CROI 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Jason E. Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN Jasjit Gill, BSPharm, PharmD
Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 10, 2022 Expired: May 9, 2023

Expert selections of important HIV data from CROI 2022, including current and investigational strategies for prevention, ART, comorbidities, and cure

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Daniel R. Kuritzkes, MD
Released: May 2, 2022

Clinical Care Options (CCO) expert audio: Drs Cristina Mussini and William Short discuss key data and recommendations for the use of novel therapies for HIV treatment and prevention

Cristina Mussini, MD William R. Short, MD, MPH, AAHIVS Released: May 2, 2022

Slides from Dr Michelle Collins-Ogle and Clinical Care Options (CCO): There are key HIV management considerations for pediatric patients

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: April 29, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings